Pfizer-backed Priovant Receives FDA Approval for Lead Asset
Source Summary
Priovant, a company backed by Pfizer, has received FDA approval for its lead asset. The specific details of the approved asset and its therapeutic indication are not provided in the source material.
Why it matters
FDA approval of a lead asset represents a significant regulatory milestone for a drug development company and its backers.
